PCH
IMDX

Polar Capital Holdings’s Insight Molecular Diagnostics IMDX Stock Holding History

Polar Capital Holdings’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,321
Closed -$231 – 479
2021
Q4 		$231 Hold
5,321
– – ﹤0.01% 413
2021
Q3 		$379 Buy
5,321
+1,995
+60% +$183K ﹤0.01% 340
2021
Q2 		$382 Hold
3,326
– – ﹤0.01% 343
2021
Q1 		$345K Buy
+3,326
New +$316K ﹤0.01% 313

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Polar Capital Holdings's IMDX Position: Q1 2022 in Review

Polar Capital Holdings sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 5,321 shares — an estimated $231 sold.

Polar Capital Holdings first reported a position in IMDX in Q1 2021 and held it in 4 quarters. The position peaked at $345K in Q1 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Polar Capital Holdings reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Polar Capital Holdings sold 5,321 Insight Molecular Diagnostics shares in Q1 2022, an estimated $231.
  • Polar Capital Holdings first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 4 quarters.
  • Polar Capital Holdings's Insight Molecular Diagnostics position peaked at $345K in Q1 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Polar Capital Holdings's 13F filing for Q1 2022, filed 16 May 2022.